These stocks reporting next week have a history of topping analysts' expectations

Earnings season kicks off with ~30 S&P 500 companies, including Intuitive Surgical and major banks. Intuitive Surgical has beaten analysts’ estimates 89% of the time and shares gained 2.58% after prior reports, with analysts (23/34 buys/strong buys) pointing to a self-reinforcing dV5-driven cycle; consensus targets imply ~38% upside. For Morgan Stanley, Bank of America lifted Q2 EPS to $2.81 from $2.71 and raised its price target to $250 (over 12% upside), citing wealth momentum and strong Asia trading.

Analysis

The market usually pays a premium for “habitual beaters,” but that premium can become a trap when consensus is already leaning on the same pattern. In the near term, the best setup is not the highest beat rate; it is the name where earnings quality can still re-rate the multiple rather than just clear a low bar. That makes ISRG the cleanest structural story: recurring revenue and utilization can convert a solid print into longer-duration multiple support, but only if procedure growth and upgrade adoption remain ahead of hospital capex scrutiny.

For MS, the key mechanism is mix shift: wealth management should dampen earnings volatility relative to more trading-dependent peers, while any capital efficiency improvement in FICC can push returns on equity higher without needing a big market rally. The risk is that trading and underwriting are being asked to carry too much of the quarterly narrative; if those lines are merely okay, the stock can still lag because the market is paying for a steady compounding franchise, not just an earnings beat. BAC is more of a barometer than a standout — better for sector read-through than as the best single-name expression.

Contrarian view: this screen may be over-indexing on historical beat frequency, which is backward-looking and increasingly crowded. NFLX, BAC, and GS can all post acceptable numbers and still underperform if guidance or forward engagement disappoints, while ISRG and MS are the only names here with a clearer path to post-print multiple support. The biggest falsifier for the bullish setup is a print that is “good but not accelerating” — in that case, the pre-earnings optimism gets sold quickly, especially if the broader tape is risk-off.

Key Decisions for Investors

• Long ISRG into the print only on a pre-earnings pullback of 3-5%; target a 1-2 week reaction move, with a thesis that a beat plus any upgrade-cycle commentary can sustain a 5-8% gap. Falsifier: procedure growth or utilization commentary that fails to improve versus last quarter.
• Pair trade: long MS / short GS into earnings week for a 1-3 month relative-value view. MS offers the cleaner recurring-earnings profile; the pair works if wealth management and capital-efficient trading offset broader IB softness. Falsifier: a broad capital-markets rebound that lifts GS more than MS.
• If implied vol is elevated post-runup, consider selling cash-secured puts or put spreads on ISRG rather than chasing common stock; the stock tends to reward clean execution, but the risk/reward is worse if the print is simply in-line. Use a 1-2 month horizon.
• Watch BAC and GS as sector signals rather than alpha bets; if both banks guide conservatively on trading/IB, reduce long exposure to financial beta and rotate toward MS or defensive quality. Trigger: any negative revision to 2024/2025 fee income commentary.
• Avoid buying NFLX solely for the earnings setup unless engagement/margin data are clearly improving; this is the kind of name where strong headline growth can still disappoint if content amortization or subscriber mix pressures margins.